Irbesartan Hydrochlorothiazide Dawa (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing vasoconstriction and aldosterone‑driven sodium retention. This leads to relaxed blood vessels and reduced blood pressure.

The prescribed dose is determined by the treating clinician based on the individual’s blood‑pressure goals, renal function, and overall health status. Dosage adjustments are made according to clinical response and tolerability.

Safety in pregnancy has not been established and the product is generally avoided unless the potential benefit justifies the risk. Caution is also advised during breastfeeding; the decision should be made by a healthcare professional.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent therapy, the Irbesartan/HCTZ combination offers additive blood‑pressure reduction, potentially improving control with a single tablet and simplifying regimens. It may be preferred when both renin‑angiotensin blockade and diuresis are desired.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the package remains tightly closed until use.

The medication is taken orally, usually once daily, with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the timing without medical advice.

Serious adverse events can include severe dehydration, acute kidney injury, marked electrolyte disturbances such as hyperkalaemia, and allergic reactions ranging from rash to anaphylaxis. Prompt medical attention is required if these occur.

The product should be avoided in patients with known hypersensitivity to either component, severe renal impairment, hyperkalaemia, or in women who are pregnant unless the benefit outweighs the risk. Clinicians should also assess for contraindications before initiating therapy.